Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients ...

In a recent article titled “ Big Pharma says ‘Thanks, but No Thanks’ to their own HEOR groups, ” Professor Scott Ramsey from ...

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

Statistically significant means there is a very high likelihood the drug impacted its target. But if data are not clinically ...

The energy component—and cost—associated with artificial intelligence should not be overlooked in all the excitement.

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

Monica Martin de Bustamante, senior partner and head of advisory at Trinity Life Sciences, spoke with Pharmaceutical ...

In this Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, speaks about how distrust and uncertainty ...

New cases are still being recorded, and the impact of long COVID has yet to be fully determined. Invivyd announced a ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...